

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT EXCLUSIVE LICENSE AGREEMENT FOR SYH2039 WITH BEIGENE

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the Group has entered into an exclusive license agreement (the “**Agreement**”) with BeiGene Switzerland GmbH (“**BeiGene**”) for the global development, manufacture and commercialization of a novel and highly selective methionine adenosyltransferase 2A (MAT2A) inhibitor (SYH2039) (the “**Compound**”) and any pharmaceutical product subsequently developed that is comprised of or contains the Compound (the “**Products**”).

Pursuant to the Agreement and subject to the terms and conditions, the Group agreed to grant an exclusive license to BeiGene to develop, manufacture and commercialize the Compound and the Products worldwide. The Group will receive upfront payments totaling US\$150 million, and is also eligible to receive potential development milestone payments of up to US\$135 million and commercialization milestone payments of up to US\$1,550 million, plus tiered royalties based on the annual net sales of the Products.

ABOUT SYH2039

SYH2039 is a clinical-stage drug candidate of the Group using its AI-driven small molecule drug design platform. This platform used AI technology to analyze the binding patterns of target proteins with compound molecules and conduct targeted optimization of the drug-like properties, and ultimately selected a highly active and selective small molecule MAT2A inhibitor. SYH2039 targets solid tumors that have a mutation called MTAP deletion, which is estimated to be present in 15% of all cancer types with the most common including glioblastoma, pancreatic cancer and non-small cell lung cancer. Preclinical studies have demonstrated that SYH2039 can effectively inhibit the growth of MTAP-deficient tumor cells in various cancers including non-small cell lung cancer, gliomas, gastroesophageal cancer, pancreatic cancer and bladder cancer, with remarkable in vivo and in vitro activities, as well as good pharmacokinetics (PK) properties and safety, positioning it as a potential best-in-class oncology drug. SYH2039 can be used alone or in combination with a variety of drugs including second-generation PRMT5 inhibitors to achieve synergistic effect. SYH2039 has already initiated a Phase I clinical study in China, with preliminary data demonstrating favorable safety, PK profile and excellent PK-PD marker correlation. Due to huge clinical needs arising from the lack of effective targeted therapies for MTAP-deficient tumors, SYH2039 has a promising clinical development value.

ABOUT BEIGENE

BeiGene, Ltd. (Hong Kong Stock Exchange: 06160; Shanghai Stock Exchange: 688235; NASDAQ: BGNE), which plans to change its name to BeOne Medicines Ltd., is a global oncology company that is discovering and developing innovative treatments that are more accessible and affordable to cancer patients worldwide. BeiGene Switzerland GmbH is a wholly-owned subsidiary of BeiGene, Ltd.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 12 December 2024

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Mr. CAI Xin and Mr. CHEN Weiping as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.